UPCOMING WEBINAR: RESEARCH BREAKTHROUGHS FROM THE 2025 ASCO® ANNUAL MEETING | REGISTER NOW UPCOMING WEBINAR: RESEARCH BREAKTHROUGHS FROM THE 2025 ASCO® ANNUAL MEETING |
Hero Background

PROVIDERS /// ONCOLOGY

Creating more options for your patients

Our collection of offerings uncover unique insights that empower you to customize treatment for individual patients, throughout their cancer journey.

A comprehensive solution for all of your precision oncology needs

  1. GENOMIC PROFILING

    We deliver a comprehensive view of your patients through our tissue and liquid tests, DNA and RNA sequencing, somatic and germline tests, tumor-normal matched profiling, and MRD and monitoring test options.

  2. ALGORITHMIC TESTS

    We leverage our growing database to create specialized algorithms like Homologous Recombination Deficiency (HRD), Tumor Origin (TO), and DPYD, with more algorithms in development.

  3. TEMPUS HUB

    We offer a fast, reliable platform for ordering Tempus tests, accessing patient insights, and utilizing our AI-driven technologies seamlessly.

  4. TEMPUS ONE

    The first generative AI-enabled clinical assistant that provides access to patient insights directly at your fingertips.

  5. EHR INTEGRATION

    We offer easy access to current treatment options and relevant insights through our integration and connectivity capabilities.

  6. TEMPUS+

    We provide select participating institutions with access to technical support, customized to meet the unique needs and goals of your cancer center.

  7. CLINICAL TRIAL MATCHING

    We bring just-in-time clinical trial options to patients based on clinical and molecular data, for enrollment at your institution, through our TIME Trial Program—in days instead of months.

  8. DIGITAL PATHOLOGY

    We are developing AI capabilities to help pathologists find actionable markers in specimens to identify potential patients for clinical trials or precision therapeutics.

  9. CARE PATHWAY SOLUTIONS

    We empower physicians to deliver the next step in a patient’s care journey with our AI-enabled care pathway intelligence platform.

Streamlining your workflow

One order. One platform. One financial assistance program.

Browse our FAQs
Financial Assistance

Tempus is committed to providing easy and affordable access to our tests and services.

  • Apply for financial assistance online at access.tempus.com.

  • If approved, you will know immediately about the maximum out of pocket cost of your testing.

  • Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.

Authorization for Medical Records: Through access.tempus.com, you will be directed to our Notice and Authorization for Medical Records authorization form. This optional form allows us to request outcomes and other medical records from your health care providers. Please see the form for more information.

Working with the top hospitals in North America

In the rapidly changing world of cancer care and precision medicine, Tempus is the established leader. They provide rapid, accurate results while also continuing to develop innovative strategies to improve patient outcomes. With a focus on both clearly defining actionable mutations and extending treatment options by matching specific patients to specific local and national studies, Tempus is directly changing the patients' lives.

Joseph K Hofmeister, MD, OhioHealth

Working with the top hospitals in North America

Breast cancer care has involved use of biomarkers for years in order to determine appropriate therapy. Genomic information has now been added to the list of crucial biomarkers needed to know how to treat metastatic breast cancer patients with the approval of targeted therapy for BRCA and PIK3CA mutations. Having this information also gives a patient the best opportunity to consider one of numerous biomarker driven clinical trials. These options allow as personalized an approach to treatment as possible and I have no doubt that genomic data will continue to transform the way patients are treated as our field moves forward.

Megan Kruse, MD, Cleveland Clinic

  • 6.5K+

    oncologists rely on Tempus as their precision medicine partner

  • 30K+

    patients have been identified for potential enrollment into clinical trials in our network

  • 8M+

    de-identified research records

  • 40+

    operational countries across North, Central and South America, Europe, the Middle East, and Asia

image description

Our Science

view all publications
  • UPCOMING WEBINAR:

    Genetic and Oncogenic Features of RASGRF Fusions

    In this study, we provide insights about the tissue distribution, structural diversity, and oncogenic mechanisms of RASGRF fusions.

    Read more
  • UPCOMING WEBINAR:

    Defining Non–small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data

    In this study, we leveraged clinical and real-world data to study ICI resistance and insights suggest a clear divergence of the tumor microenvironment in patients with primary versus acquired resistance and a potential role of myeloid cells in the PD-L1<1% population.

    Read more
  • UPCOMING WEBINAR:

    Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non–Small Cell Lung Cancer

    In a large, real-world cohort of advanced NSCLC patients tested with CGP, the treatment adherence rate to matched NCCN-recommended targeted therapy was high. This study highlights the importance of CGP testing in identifying variants to provide timely matched targeted therapy.

    Read more
  • UPCOMING WEBINAR:

    Circulating Tumor DNA (ctDNA) Dynamics Predict Clinical Recurrence in Liver-Limited Metastatic Colorectal Cancer (mCRC) Patients Resected After First-Line Systemic Treatment

    This study showed that MRD status predicts clinical recurrence and correlates to RFS at TPoS in LLD mCRC pts resected after first-line systemic therapy.

    Read more
  • UPCOMING WEBINAR:

    Development and Validation of The Immune Profile Score (IPS), a Novel Multiomic Algorithmic Assay For Stratifying Outcomes in a Real-World Cohort of Patients With Advanced Solid Cancer Treated With Immune Checkpoint Inhibitors

    Study results demonstrate that IPS is a generalizable multiomic biomarker that can be widely used clinically as a prognosticator of ICI-based regimens.

    Read more
  • UPCOMING WEBINAR:

    Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status – a Real-World Analysis in Patients With Advanced NSCLC

    This study found that outcomes following 1L therapy in KRASmt advanced NSCLC varied based on PD-L1 levels and the presence of STK11 and KEAP1 co-mutations, indicating that KRASm NSCLC represents a heterogeneous disease.

    Read more

Featured News and Events

view all news
  • UPCOMING WEBINAR:

    Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer

    Tempus AI, Inc. announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Now, the platform will support five different biomarker testing gaps specific to breast cancer with the goal of helping physicians deliver guideline-directed medical care to eligible patients.

    Read more
  • UPCOMING WEBINAR:

    Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

    Tempus announced a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus’ growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD).

    Read more
  • UPCOMING WEBINAR:

    Introducing Tempus One in the EHR with Integrated Guidelines

    Tempus announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions.

    Read more
  • UPCOMING WEBINAR:

    Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

    Tempus announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality.

    Read more
  • UPCOMING WEBINAR:

    A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 Years

    Tempus announced its participation in almost 1,500 research projects in just the last ten years. This milestone highlights Tempus’ ongoing commitment to accelerating scientific discovery and delivering data-driven insights that improve patient outcomes.

    Read more
  • UPCOMING WEBINAR:

    Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

    Tempus announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers

    Read more

Validations and Resources

view all resources
  • UPCOMING WEBINAR:

    Tempus xT Validation

    Our Tempus xT assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available.

    Read more
  • UPCOMING WEBINAR:

    Tempus xF Validation

    Our non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients.

    Read more
  • UPCOMING WEBINAR:

    Standard Requisition Form

    We offer an easy ordering process which allows you to order any of somatic and germline panels along with our add-on tests like HRD, TO and DPYD.

    View here

Partnering with Tempus is investing in the future

Every new test and data point strengthens our algorithms, predictions, and recommendations to improve treatment options for future patients.